Lonza
A large-scale cell culture manufacturing site for the production of monoclonal antibodies and recombinant proteins. Acquired by Lonza Group in 2008.
Health & Wellness
Moderna
Pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. Listed on NASDAQ in 2018.
Nuvation Bio
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates to improve the quality of life and survival for people with cancer.
I-MAB Biopharmaceutical
I-Mab is a full-stack biopharmaceutical company equipped to discover and develop best- and first-in-class biologics with global potential to treat cancer and auto-immune diseases.
I-MAB Biopharmaceutical Read More »
Engine Biosciences
Deciphering complex biology with NetMAPPR platform, integrating data science, machine learning, high-throughput experiments, combinatorial genetics, and drug discovery, to yield promising drug targets for precision oncology therapeutics.
Engine Biosciences Read More »
US2.ai
US2.AI (formerly eko.ai) is automating the fight against heart disease, using AI software to simplify and democratize ultrasound of the heart, the most commonly used tool for the detection of cardiovascular risk.
Aetion
Aetion is a health care technology company that delivers real-world evidence for biopharma companies, payers, regulators, and HTA agencies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value across the product life cycle.
Nuevocor
Nuevocor is an IND-stage biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expanding to Europe.
MiRXES
MiRXES is a leading developer of RNA-powered tests for disease early detection, with strong pipelines in multiple cancer types, as well as in cardiovascular, metabolic and infectious diseases. MiRXES is headquartered in Singapore, with operations in China, Japan and the United States, as well as commercial activities in over 45 countries globally.
